GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,516.00
Bid: 12,304.00
Ask: 12,600.00
Change: 0.00 (0.00%)
Spread: 296.00 (2.406%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,516.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FOREX-Dollar firms as U.S. yields tick up ahead of Fed guidance

Wed, 17th Mar 2021 08:50

* Dollar firm after three days of gains ahead of Fed
* Fed 2023 rates projections under scrutiny
* Euro may be hampered by delay in vaccine rollouts
* Graphic: World FX rates https://tmsnrt.rs/2RBWI5E

(Adds comment; updates prices)
By Julien Ponthus
LONDON, March 17 (Reuters) - The U.S. dollar firmed on
Wednesday with 10-year Treasury yields close to 13-month highs
ahead of a Federal Reserve policy meeting which could shed some
light on the timing of future rate hikes and the central bank’s
tolerance for rising yields.
With Fed policymakers expected to forecast the fastest U.S.
economic growth in decades in the wake of COVID-19 vaccinations
and $1.9 trillion in new stimulus, market participants will be
focused on clues that the central bank could start raising rates
in 2023, earlier than it had said.
In any event, expectations of a faster-than-expected
economic recovery will likely weigh.
"U.S. yields might receive further upwards thrust and pull
the dollar along with them in the absence of a clear commitment
on the part of the Fed that a further rise in yields is
undesirable", Commerzbank Antje Praefcke analyst wrote in a
morning note.
She added that because the European Central Bank had in
contrast committed to increase the pace of bond buying to keep a
lid on rising yields, the euro might suffer against the dollar
in the short term.
The euro was down 0.07% at $1.1893 after declining in
the past three sessions.
Hurt by a possible delay in the European Union's vaccination
effort, the euro seemed set to test last week's 3 1/2-month low
of $1.18355.
Europe's medicines watchdog will release results of its
investigation into incidents of bleeding, blood clots and low
platelet counts in recipients of AstraZeneca's
coronavirus vaccine on Thursday afternoon.
Europe's painful recovery from the pandemic is in sharp
contrast with other economies which seem less dependant on
monetary stimulus to pull though.
The Bank of Canada for instance is likely to reduce its bond
purchases as soon as next month, strategists say.
In morning trades in Europe, the dollar index ticked up
0.09% and stood at 91.953, having already risen for three
straight sessions on support mainly from elevated U.S. bond
yields.
Benchmark 10-year Treasury yields were also
ticking up at 1.6340%. They had reached 1.6420% on Friday for
the first time since February 2020.
Against the yen, the greenback firmed 0.15% to 109.14 yen
, hovering near nine-month highs hit this week.
The British pound was up 0.14% at $1.3914 recovering
from profit-taking after it hit a near three-year high last
month on the back of a fast vaccine rollout.
Commodity-linked currencies including the Australian dollar
, the New Zealand dollar and the Canadian dollar
eased slightly against the U.S. dollar, tracking weakness
in commodity prices.
In the cryptocurrency market, bitcoin fell 2.1%
to $55,708.79, slipping further away from a record high of
$61,781.83 hit on Saturday.

========================================================
Currency bid prices at 843 GMT
Description RIC Last U.S. Close Pct Change YTD Pct High Bid Low Bid
Previous Change
Session
Euro/Dollar $1.1894 $1.1903 -0.08% -2.66% +1.1908 +1.1887
Dollar/Yen 109.1250 109.0200 +0.12% +5.67% +109.2000 +109.0950
Euro/Yen 129.80 129.75 +0.04% +2.25% +129.9300 +129.7200
Dollar/Swiss 0.9279 0.9248 +0.34% +4.89% +0.9280 +0.9248
Sterling/Dollar 1.3914 1.3895 +0.14% +1.85% +1.3929 +1.3880
Dollar/Canadian 1.2461 1.2448 +0.10% -2.14% +1.2462 +1.2434
Aussie/Dollar 0.7729 0.7746 -0.19% +0.49% +0.7747 +0.7724
NZ Dollar/Dollar 0.7182 0.7190 -0.11% +0.01% +0.7194 +0.7174


All spots
Tokyo spots
Europe spots
Volatilities
Tokyo Forex market info from BOJ


(Reporting by Hideyuki Sano in Tokyo and Sagarika Jaisinghani
in Bengaluru; Editing by Sam Holmes, Gerry Doyle and Andrew
Cawthorne)

More News
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.